Existing studies indicated that alterations in cyclins, TP53, and Rb genes are ubiquitous in BLCA, particularly in MIBC with higher frequency, and therapy targeting against aberrant cell-cycle regulators may be beneficial in BLCA. Here, RB1 is linked to bladder transitional cell carcinoma.